Piper Sandler analyst David Amsellem reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $43.00. The company’s shares closed yesterday at $28.07.
According to TipRanks, Amsellem is an analyst with an average return of -2.9% and a 42.97% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Supernus Pharmaceuticals, and Axsome Therapeutics.
Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $42.09 and a one-year low of $21.99. Currently, Supernus Pharmaceuticals has an average volume of 379.2K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SUPN in relation to earlier this year. Most recently, in November 2023, Frederick Hudson, a Director at SUPN sold 9,093.00 shares for a total of $259,150.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals (SUPN) Company Description:
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Read More on SUPN:
